ACOG Endorses Hormone Therapy as First-Line Menopause Care

ACOG Issues Strong Rating for Menopause Hormone Therapy

Hormone therapy is now recommended as a primary option for treating hot flashes, night sweats, and related sleep disruptions. The American College of Obstetricians and Gynecologists (ACOG) released the updated clinical guidelines following a review of current patient outcomes. ACOG assigned hormone therapy a strong rating, indicating that expected benefits outweigh potential health risks for most symptomatic women.

Vasomotor symptoms affect between 50% and 92% of women during menopause. Sleep disturbances and depressive symptoms occur frequently alongside these physical changes. The updated document serves as the most comprehensive clinical advice on menopause management released by the organization to date.

Timing Guidelines Shift Away from Strict Duration Limits

ACOG advises that candidates for hormone therapy initiate treatment before age 60 or within 10 years of menopause onset. This timing window helps maximize symptom relief while minimizing cardiovascular and thrombotic risks. Clinicians evaluate individual medical history, including baseline risks for heart disease, breast cancer, and stroke, before prescribing.

The guidance marks a clear shift from the 2014 recommendation. That previous stance instructed physicians to prescribe the lowest effective dose for the shortest possible duration. The new protocol replaces rigid duration caps with periodic clinical check-ins, allowing selected patients to continue treatment past age 60 if symptoms persist.

Nonhormonal Alternatives and Evaluated Therapies

Patients who cannot take hormones have access to newer nonhormonal prescription drugs that target brain signaling pathways. Fezolinetant and elinzanetant block specific neurokinin receptors involved in body temperature control. Certain antidepressant medications also demonstrate efficacy for reducing hot flashes and addressing co-occurring depressive symptoms.

Nonpharmacologic options provide modest adjunctive benefits for symptom management when used alongside medical treatment. The guidelines review several nonhormonal interventions that patients frequently ask about:

• Cognitive behavioral therapy and clinical hypnosis show support for managing symptom distress.
• Mindfulness practices, structured exercise, and acupuncture offer limited evidence of direct symptom reduction.
• Plant-based phytoestrogens and over-the-counter herbal supplements lack verified evidence for safety or efficacy.
• Herbal blends remain exempt from mandatory purity testing by the Food and Drug Administration (FDA).

Clinical Caveats and Health Factors

Hormone therapy remains contraindicated for women with a history of blood clots, stroke, or hormone-sensitive cancers. Personal health risks require individualized assessment before starting any therapeutic regimen. ACOG notes that socioeconomic status, race, and cultural background also influence symptom presentation and access to clinical care.

This release focuses primarily on systemic vasomotor and mood symptoms. The organization plans to publish dedicated guidelines in 2027 concerning genitourinary syndrome of menopause, which encompasses vaginal dryness and recurrent urinary tract infections. Talk to your clinician about your personal health history to evaluate whether hormone therapy fits your symptom profile.